AbbVie Inc. Capital expenditures

Capital expenditures of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.


Highlights and Quick Summary

  • Capital expenditures for the quarter ending March 30, 2021 was $-188 Million (a -32.62% decrease compared to previous quarter)
  • Year-over-year quarterly Capital expenditures increased by 6.21%
  • Annual Capital expenditures for 2020 was $-798 Million (a 44.57% increase from previous year)
  • Annual Capital expenditures for 2019 was $-552 Million (a -13.48% decrease from previous year)
  • Annual Capital expenditures for 2018 was $-638 Million (a 20.6% increase from previous year)
  • Twelve month Capital expenditures ending March 30, 2021 was $-861 Million (a 7.89% increase compared to previous quarter)
  • Twelve month trailing Capital expenditures increased by 39.1% year-over-year
Trailing Capital expenditures for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
$-861 Million $-798 Million $-682 Million $-619 Million
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital expenditures of AbbVie Inc.

Most recent Capital expendituresof ABBV including historical data for past 10 years.

Interactive Chart of Capital expenditures of AbbVie Inc.

AbbVie Inc. Capital expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-188.0
2020 $-279.0 $-217.0 $-177.0 $-125.0 $-798.0
2019 $-163.0 $-154.0 $-128.0 $-107.0 $-552.0
2018 $-123.0 $-282.0 $-114.0 $-119.0 $-638.0
2017 $-182.0 $-126.0 $-126.0 $-95.0 $-529.0
2016 $-114.0 $-113.0 $-131.0 $-121.0 $-479.0
2015 $-145.0 $-127.0 $-115.0 $-145.0 $-532.0
2014 $-153.0 $-180.0 $-142.0 $-137.0 $-612.0
2013 $-151.0 $-133.0 $-119.0 $-88.0 $-491.0
2012 $-95.0 $18.0 $-94.0 $-162.0 $-333.0
2011 $-104.41 $-63.17 $-91.09 $-96.85 $-356.0
2010 $-448.14 $-448.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.